Product Description
anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02817633)
Mechanisms of Action: LAG3 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Colorectal Cancer|Lung Cancer|Ovarian Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03250832 |
CITRINO | P1 |
Completed |
Ovarian Cancer|Lung Cancer|Colorectal Cancer |
2022-06-02 |
50% |
2023-05-07 |
Primary Completion Date|Primary Endpoints |